Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study
In brief
Chemo plus immunotherapy more than doubles survival after SCLC transformation (17 vs 9 months)
In a real-world cohort of 59 EGFR-mutant NSCLC patients who progressed to small-cell lung cancer, adding an immune checkpoint inhibitor to carboplatin-etoposide raised the response rate to 71% and extended median post-transformation survival to 17 months, compared with 9 months for chemotherapy alone. The finding challenges prior doubts about immunotherapy efficacy, but prospective trials are needed.
- Journal
- Lung cancer (Amsterdam, Netherlands) (Q1)
- Published
- 23 August 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Nazan Demir, Cevat İlteriş Kıkılı, Fatih Kemik, Bahadır Köylü, Deniz Tural, Şahin Laçin, et al.
- PMID
- 42664544
- DOI
- 10.1016/j.lungcan.2026.109590
Why clinicians should know about it
- Picked for Histology (top studies of the week, 30 August 2026): High-quality evidence in a top journal
Abstract
BACKGROUND: Histologic transformation to small-cell lung cancer (SCLC) is an aggressive resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) therapy in EGFR-mutant non-small cell lung cancer (NSCLC). Real-world data on this population remain limited. METHODS: We conducted a multicenter retrospective cohort study across 26 oncology centers (2016-2025). Patients with histologically confirmed EGFR-mutant NSCLC and biopsy-proven SCLC transformation were included. Primary endpoints included PFS during first-line EGFR-TKI therapy (PFS1), time to transformation (TTT), PFS after transformation (PFS2), overall survival from metastatic diagnosis (OS-1), post-transformation survival (OS-2), and overall survival from initial NSCLC diagnosis (OS-3). Survival was assessed with Kaplan-Meier and Cox regression analyses. RESULTS: A total of 59 patients were included (median age 57.8 years; 52.5 % male; exon 19 deletion 76.3 %). Median PFS1 was 14.0 months (95 % CI, 11.3-16.7); median TTT was 22.0 months (range, 3-110). Following transformation, 54 patients (91.5 %) received systemic therapy: carboplatin plus etoposide (CE) alone in 37 (68.5 %) and CE plus immunotherapy (atezolizumab, durvalumab, or durvalumab plus osimertinib) in 16 (29.6 %). ORR was 37.8 % with CE alone versus 71.4 % with CE plus immunotherapy; median PFS2 was 5.0 months (95 % CI, 3.5-6.5). Median OS-1 was 38.0 months (95 % CI, 32.0-53.0). Median OS-2 was 11.0 months (95 % CI, 7.5-14.5) overall, and significantly longer with CE plus immunotherapy versus CE alone (17.0 vs. 9.0 months; log-rank p = 0.026; HR 0.327, 95 % CI 0.139-0.767). Median OS-3 was 41.1 months. CONCLUSION: In this large multicenter cohort, adding immune checkpoint inhibitors (ICIs) to CE was associated with improved post-transformation survival, challenging prior evidence of immunotherapy inefficacy in this setting. Systematic re-biopsy at progression on EGFR-TKI therapy is essential to confirm transformation and guide treatment. Prospective biomarker-driven studies are warranted.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.